[HTML][HTML] Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
BACKGROUND Hepatitis C virus (HCV) is a leading cause of worldwide liver-related
morbidity and mortality. The World Health Organization released an integrated strategy …
morbidity and mortality. The World Health Organization released an integrated strategy …
Boceprevir for chronic genotype 1 hepatitis C virus in the current health care setting in Greece: a cost-effectiveness analysis
K Athanasakis, SA Ferrante, II Kyriopoulos, I Petrakis… - Clinical …, 2015 - Elsevier
Purpose Boceprevir, as an add-on to the standard of care (SOC) for chronic genotype 1
hepatitis C virus (G1 HCV), pegylated interferon+ ribavirin for 48 weeks (PEG+ RBV), has …
hepatitis C virus (G1 HCV), pegylated interferon+ ribavirin for 48 weeks (PEG+ RBV), has …
Cost–effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
Aim: This study assessed the clinical impact and cost–effectiveness of switching from
tenofovir disoproxil fumarate (TDF) to either tenofovir alafenamide (TAF) or entecavir (ETV) …
tenofovir disoproxil fumarate (TDF) to either tenofovir alafenamide (TAF) or entecavir (ETV) …
Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naive patients …
EIH Akpo, K Cerri, J Kleintjens - PharmacoEconomics, 2015 - Springer
Objectives Studies on medical resource utilization (MRU) and related costs are important for
evaluating the potential patient management and cost-effectiveness implications of antiviral …
evaluating the potential patient management and cost-effectiveness implications of antiviral …
[HTML][HTML] Real-life cost of managing chronic HCV infection in Greece prior to Direct-Acting Antivirals (DAAs): an undeniable truth of spending more for less
K Souliotis, S Siakavellas, C Golna, E Manesis… - Hippokratia, 2018 - ncbi.nlm.nih.gov
Purpose: Chronic hepatitis C virus (HCV) infection is a major public health challenge across
the world. Before the introduction of Direct-Acting Antivirals (DAAs), managing and treating …
the world. Before the introduction of Direct-Acting Antivirals (DAAs), managing and treating …
Infeção Pelo Vírus da Hepatite C: Evolução dos Modelos de Avaliação Económica
ALDSF Pinto - 2017 - search.proquest.com
INFEÇÃO PELO VÍRUS DA HEPATITE C: EVOLUÇÃO DOS MODELOS DE AVALIAÇÃO
ECONÓMICA Ana Luísa Dos Santos Ferreira Pinto Disse Page 1 UNIVERSIDADE DE …
ECONÓMICA Ana Luísa Dos Santos Ferreira Pinto Disse Page 1 UNIVERSIDADE DE …
[HTML][HTML] Managing Hepatitis C Patients in Greece: A Budget Impact Analysis of Simeprevir plus Pegylated Interferon/Ribavirin Regimen at Early Stages of the Disease
M Geitona, H Kousoulakou, I Goulis… - Health, 2017 - scirp.org
Objectives: To identify local resource use such as pharmaceutical treatment, medical follow-
up, and patient hospitalization and estimate the budget impact of simeprevir (SMV) plus …
up, and patient hospitalization and estimate the budget impact of simeprevir (SMV) plus …
[PDF][PDF] Best Practice/Intervention: Akpo EI. et al.(2015) Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in …
A Part, B Part - cagh-acsm.org
Objectives Studies on medical resource utilization (MRU) and related costs are important for
evaluating the potential patient management and cost-effectiveness implications of antiviral …
evaluating the potential patient management and cost-effectiveness implications of antiviral …